PPCA | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

471 results for “PPCA”

Trials

View all 411 →

Evaluation of Perforator Phase Contrast Angiography in Developing Surgery Plans for Patients With Breast Cancer Undergoing Breast Reconstruction With Free-Flap Methods After Mastectomy

First posted Aug 21, 2019

Not yet recruiting

Personalized Closed-Loop Brain Stimulation for Patients With Primary Progressive Aphasia

10 participants · First posted Apr 6, 2026

Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

88 participants · First posted Jun 2, 2009

Drugs

View all 49 →

PPCA-03

PQCA

pPCV

Organizations

Ipca Laboratories Ltd

Kenya

IPCA LABORATORIES LIMITED

India

IPCA PHARMA (AUSTRALIA) PTY LTD

Australia

News

Amlogenyx Reports Promising Preclinical Data for AM805 Gene Therapy in Alzheimer's Disease Treatment

Nature Study Validates LIXTE's PP2A Inhibitor LB-100 for Enhanced Cancer Immunotherapy

Lixte Biotechnology's LB-100 Shows Promise in Multiple Cancer Indications Through Novel PP2A Inhibition

Page 1 of 48